BioCentury
ARTICLE | Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

November 8, 2018 8:09 PM UTC

University of Pennsylvania spinout Cabaletta Bio Inc. (Radnor, Pa.) emerged from stealth with an untranched $38 million series A to develop CAR T therapies for B cell-mediated autoimmune diseases.

Cabaletta's co-founders include Michael Milone, an associate professor of pathology at Penn and co-inventor of CAR T therapy Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS; SIX:NOVN); Aimee Payne, an associate professor of dermatology at Penn; and Steven Nichtberger, who is also the company's chairman and CEO...

BCIQ Target Profiles

Desmoglein 3 (DSG3)